274 related articles for article (PubMed ID: 19466913)
1. Targeting histone deacetylases for heart failure.
Bush EW; McKinsey TA
Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
[TBL] [Abstract][Full Text] [Related]
2. The biology and therapeutic implications of HDACs in the heart.
McKinsey TA
Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
Gallo P; Latronico MV; Gallo P; Grimaldi S; Borgia F; Todaro M; Jones P; Gallinari P; De Francesco R; Ciliberto G; Steinkühler C; Esposito G; Condorelli G
Cardiovasc Res; 2008 Dec; 80(3):416-24. PubMed ID: 18697792
[TBL] [Abstract][Full Text] [Related]
4. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation.
Olson EN; Backs J; McKinsey TA
Novartis Found Symp; 2006; 274():3-12; discussion 13-9, 152-5, 272-6. PubMed ID: 17019803
[TBL] [Abstract][Full Text] [Related]
5. Derepression of pathological cardiac genes by members of the CaM kinase superfamily.
McKinsey TA
Cardiovasc Res; 2007 Mar; 73(4):667-77. PubMed ID: 17217938
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.
Kee HJ; Sohn IS; Nam KI; Park JE; Qian YR; Yin Z; Ahn Y; Jeong MH; Bang YJ; Kim N; Kim JK; Kim KK; Epstein JA; Kook H
Circulation; 2006 Jan; 113(1):51-9. PubMed ID: 16380549
[TBL] [Abstract][Full Text] [Related]
7. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.
McKinsey TA; Olson EN
J Clin Invest; 2005 Mar; 115(3):538-46. PubMed ID: 15765135
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential for HDAC inhibitors in the heart.
McKinsey TA
Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
[TBL] [Abstract][Full Text] [Related]
9. Dual roles of histone deacetylases in the control of cardiac growth.
McKinsey TA; Olson EN
Novartis Found Symp; 2004; 259():132-41; discussion 141-5, 163-9. PubMed ID: 15171251
[TBL] [Abstract][Full Text] [Related]
10. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
McKinsey TA
J Mol Cell Cardiol; 2011 Oct; 51(4):491-6. PubMed ID: 21108947
[TBL] [Abstract][Full Text] [Related]
11. Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment.
Latronico MV; Elia L; Condorelli G; Catalucci D
Int J Biochem Cell Biol; 2008; 40(9):1643-8. PubMed ID: 18514564
[TBL] [Abstract][Full Text] [Related]
12. Targeting inflammation in heart failure with histone deacetylase inhibitors.
McKinsey TA
Mol Med; 2011; 17(5-6):434-41. PubMed ID: 21267510
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Kazantsev AG; Thompson LM
Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
17. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Kee HJ; Kook H
J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
Abend A; Kehat I
Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
[TBL] [Abstract][Full Text] [Related]
19. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
Kee HJ; Eom GH; Joung H; Shin S; Kim JR; Cho YK; Choe N; Sim BW; Jo D; Jeong MH; Kim KK; Seo JS; Kook H
Circ Res; 2008 Nov; 103(11):1259-69. PubMed ID: 18849323
[TBL] [Abstract][Full Text] [Related]
20. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Bartha E; Kiss GN; Kalman E; Kulcsár G; Kálai T; Hideg K; Habon T; Sumegi B; Toth K; Halmosi R
J Cardiovasc Pharmacol; 2008 Sep; 52(3):253-61. PubMed ID: 18806606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
